Peripartum Cardiomyopathy

Authors, Journal, Affiliations, Type, DOI

• Zoltan Arany, M.D., Ph.D.
• Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia
• N Engl J Med 2024;390:154-64
• Review article (CME)
• DOI: 10.1056/NEJMra2306667

Overview

Peripartum cardiomyopathy (PPCM) is a form of acute heart failure with systolic dysfunction (LVEF <45%) occurring in the last month of pregnancy or within the first 5 months post-delivery, in the absence of preexisting cardiac dysfunction. This NEJM review by Zoltan Arany reframes pathogenesis through a vasculohormonal model, where peripartum hormonal imbalances — particularly prolactin cleavage products and placental sFlt-1 — damage the cardiac vasculature in genetically susceptible women. Approximately 15% of patients carry DCM-predisposing variants (predominantly TTN), placing PPCM on a shared genetic spectrum with dilated cardiomyopathy. Management mirrors HFrEF guideline-directed medical therapy, with bromocriptine under investigation in the REBIRTH randomised trial (expected 2026), and racial disparities in incidence and outcomes remain profound and poorly explained.

Keywords

Peripartum cardiomyopathy, heart failure, prolactin, sFlt-1, TTN, dilated cardiomyopathy, bromocriptine, racial disparities, vasculohormonal, genetic predisposition

Key Takeaways

Clinical Presentation and Evaluation

• Defined as maternal HF with LVEF <45% developing in the last month of pregnancy or in the first 5 months post-delivery, in the absence of known preexisting cardiac dysfunction; some cases occur earlier or >5 months postpartum
• Presentation mirrors HF symptoms (dyspnea, orthopnea, elevated JVP, pulmonary rales, edema) — diagnosis is often delayed because symptoms overlap with normal pregnancy
• 60–90% of cases occur after delivery, with the highest incidence in the first postpartum week
• Diagnosis is one of exclusion; differential includes preexisting structural heart disease, preeclampsia-induced pulmonary edema (no systolic dysfunction), PE, SCAD, and toxic CMP
• Echocardiography is the primary diagnostic modality; BNP is usually elevated and can prompt suspicion; endomyocardial biopsy is rarely needed
• CMR can evaluate systolic function and structure; late gadolinium enhancement findings consistent with myocarditis are uncommon, arguing against myocarditis as the primary cause
• No diagnostic biomarker is currently available; AI-ECG and high-sensitivity troponin are under investigation
• Genetic testing should be considered in most cases, even without a family history

Epidemiology

• Complicates ~1 in 2000 births worldwide; rates as high as 1 in 300 in Haiti and 1 in 100 in parts of Nigeria
• In the US, Black women are 4× more likely to develop PPCM than White women; twice as likely to have persistent cardiac dysfunction; recovery takes twice as long when it does occur
• One-third to one-half of cases occur in women with hypertensive disorders of pregnancy (including preeclampsia)
• Other strong risk factors: multiple gestations, advanced maternal age, anemia; mode of delivery is not a risk factor
• PPCM is now a leading cause of maternal death in many parts of the US and globally; accounts for ~60% of cardiogenic shock in the peripartum period
• Mortality up to 20%; highest in Black women in the US and women in less developed countries

Pathogenesis — Vasculohormonal Model

• The disorder develops predominantly after delivery, temporally discordant with hemodynamic changes of pregnancy — arguing against PPCM being simply a "failed hemodynamic stress test"
• Prolactin pathway: Cathepsin D cleaves prolactin (secreted by pituitary in late gestation and during lactation) into a 16-kDa cardiotoxic fragment → damages cardiac vasculature → cardiac ischemia + paracrine signaling → endothelial cells secrete exosomes containing miR-146a → cardiomyocyte apoptosis. Supports rationale for bromocriptine and breast-feeding cessation
• sFlt-1 pathway: Placental syncytiotrophoblasts abundantly secrete soluble fms-like tyrosine kinase 1 (sFlt-1) — a decoy receptor for VEGF — in late gestation → cardiovascular rarefaction → PPCM. Explains strong epidemiologic association with preeclampsia and multiple gestations (both contexts associated with large increases in placental sFlt-1 secretion); subclinical cardiac dysfunction in preeclampsia correlates with circulating sFlt-1
• Additional hormonal contributors: Activin A (senescence-associated, correlates with cardiac dysfunction even 1 year post-delivery in preeclampsia); progesterone (suppresses cardiac carbohydrate metabolism, promotes hypertrophy, may have direct negative-inotropic effects — sensitizes the heart to further insults); oxytocin (vasculotoxic in Marfan syndrome models, definitive PPCM role not established); reduced relaxin-2 (vasculoprotective hormone suppressed in PPCM)
• Other proposed mechanisms: Autoimmunity (anti-troponin I and anti-sarcomeric myosin antibodies), microchimerism, inflammation (proteomic analysis shows inflammatory and cholesterol metabolism pathway dysregulation), selenium deficiency (relevant mainly in parts of Nigeria)

Genetics

• ~15% of women with PPCM carry heterozygous loss-of-function variants in DCM-associated genes
• Variant frequencies are nearly identical between PPCM and DCM cohorts — supporting a shared genetic spectrum where pregnancy acts as an environmental "second hit"
• Two-thirds of identified genetic variants in PPCM lie in TTN (titin); truncated titin proteins are expressed and detectable in failing hearts
• TTN penetrance in causing disease is <5% — consistent with the need for additional genetic and environmental triggers
• FLNC and DSP variants are associated with ventricular arrhythmias in DCM; the same is likely true in PPCM — gene-specific risk stratification applies
• PPCM can be the first presentation of rare diseases: Danon's disease (LAMP2 variants) and Duchenne's muscular dystrophy (DMD variants)
• The same DCM-predisposing variants also increase susceptibility to chemotherapy-induced and alcohol-induced cardiomyopathy — suggesting a common unidentified pathophysiology
• Only ~100 genes have been targeted in PPCM sequencing cohorts; common variant landscape is poorly characterised
• Genetic testing should be offered to patients with PPCM with referral for genetic counselling; cascade testing of family members is beneficial when a pathogenic variant is identified

Management

• Volume control: Diuretics and nitrates — use with caution to avoid hypotension before delivery
• Neurohormonal blockade:
  • ACEi, ARBs, aldosterone antagonists: post-delivery only (teratogenic, contraindicated in pregnancy)
  • Hydralazine + isosorbide dinitrate: alternative for afterload reduction during pregnancy
  • Beta-blockers: routinely indicated and safe during pregnancy
  • Sacubitril-valsartan and SGLT2i: no safety data during or after pregnancy; increasingly used post-delivery by extrapolation from HFrEF GDMT
  • Most standard HF medications are compatible with breast-feeding; no safety data for newer agents (ARNi, SGLT2i)
• Anticoagulation: Hypercoagulable state in peripartum increases thrombotic risk (LV thrombus and thromboembolic events in 5–20%). Low threshold for anticoagulation — EF <30–35% or presence of atrial fibrillation
• Arrhythmia management: Wearable cardioverter-defibrillator (LifeVest) preferred over ICD given frequent cardiac recovery; ICD implantation should be delayed to assess for LV recovery
• Bromocriptine: Dopamine agonist suppressing prolactin secretion; may be considered in patients with LVEF <35%; ESC guidelines suggest consideration; US expert consensus is less uniform. REBIRTH trial (NCT05180773; n=200; bromocriptine vs placebo) expected to complete 2026
• Breast-feeding: Available data suggest breast-feeding is safe in PPCM; the theoretical benefit of prolactin suppression (by bromocriptine or cessation) must be weighed against the well-established benefits of breast-feeding (WHO/AAP recommend exclusive breast-feeding for 6 months, continued up to 2 years; withholding increases infant mortality >10× in many parts of the world)
• Labor and delivery: Multidisciplinary team (MFM obstetrician, anesthesiologist, cardiologist, advanced HF specialist); vaginal delivery is safe if hemodynamically stable; lactation is generally not contraindicated
• Advanced therapies: IABP, percutaneous VAD, ECMO, LVAD as needed; adrenergic support may be deleterious (low STAT3 sensitises to β-adrenergic toxicity)
• Medication withdrawal after recovery: Reasonable approach — wait ≥1 year after echocardiographic recovery; withdraw one agent at a time with close long-term clinical and echocardiographic follow-up; TRED-HF data (DCM) suggest risk of relapse exists

Clinical Outcomes

• 50% of patients recover LVEF >50% within 6 months; in some women, recovery takes longer or does not occur

• LVAD or cardiac transplantation required in up to 10%; post-transplant survival is inferior to age-adjusted recipients transplanted for other reasons
• Overall mortality up to 20%; highest in Black women in the US and women in low-income countries
• Indicators of adverse outcome: lower LVEF at presentation, late presentation (>1 week post-delivery), LGE on CMR, LV dilatation, RV dysfunction
• Paradoxically, co-occurrence of preeclampsia with PPCM is associated with better LV recovery but higher adverse cardiovascular events long term
• Long-term outcomes (>5 years) are poorly studied; impact on mental health is substantial — up to 50% may meet criteria for depression or PTSD; cardiac functional recovery does not guarantee complete molecular recovery (persistent dysfunction on exercise or dobutamine stress testing despite normal EF)

Subsequent Pregnancy and Counseling

• Disease recurs in 10–50% of subsequent pregnancies; recurrent disease can be worse (including death)
• Lack of full systolic recovery before subsequent pregnancy is associated with worse outcomes but is not a strong predictor
• Careful monitoring by a multidisciplinary team is likely to improve outcomes in subsequent pregnancies

Racial Disparities

• 4× higher incidence in Black vs White women in the US; 2× worse outcomes; 2× longer recovery time
• Socioeconomic factors (neighborhood deprivation, provider bias) more likely than genetic factors to drive this disparity
• Later presentation in Black women (possibly contributing to worse outcomes)
• Wider use of BNP as a diagnostic biomarker may reduce disparities by preventing delayed diagnoses

Limitations of the document

• Review article — no primary data; management recommendations largely extrapolated from non-PPCM HFrEF trials
• Most preclinical research done in murine models; human placenta differs substantially from murine placenta (less invasive, less endocrinologically active) — limiting translational validity
• Few randomized trials of PPCM-specific therapies; none conclusive
• Bromocriptine RCT evidence remains limited; REBIRTH results pending
• Genomic landscape of common variants in PPCM is poorly characterised; only ~100 genes sequenced in PPCM cohorts
• Long-term outcomes data (>5 years) are very limited
• Racial disparities are documented but causal mechanisms remain poorly understood

Key Concepts Mentioned

• entities/Peripartum-Cardiomyopathy — primary concept created from this source
• concepts/Hypertensive-Disorders-of-Pregnancy — preeclampsia/HDP as major risk factor; sFlt-1 shared mechanism

Key Entities Mentioned

• entities/DCM — shared genetic spectrum; PPCM as DCM variant triggered by pregnancy
• entities/TTN — most common genetic variant in PPCM (~2/3 of genetic cases)
• entities/FLNC — associated with ventricular arrhythmia risk in PPCM
• entities/DSP — associated with ventricular arrhythmia risk in PPCM

Wiki Pages Updated

• Created: wiki/sources/peripartum-cmp-nejm-2024.md
• Created: wiki/entities/Peripartum-Cardiomyopathy.md
• Updated: wiki/entities/DCM.md — PPCM-DCM spectrum section expanded
• Updated: wiki/concepts/Hypertensive-Disorders-of-Pregnancy.md — sFlt-1/PPCM subsection added
• Updated: wiki/sourceindex.md
• Updated: wiki/wikiindex.md